Louisiana State Employees Retirement System Boosts Stock Position in Glaukos Co. (NYSE:GKOS)

Louisiana State Employees Retirement System increased its position in Glaukos Co. (NYSE:GKOS) by 5.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,600 shares of the medical instruments supplier’s stock after acquiring an additional 1,300 shares during the quarter. Louisiana State Employees Retirement System owned about 0.05% of Glaukos worth $3,465,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GKOS. EFG Asset Management North America Corp. lifted its position in shares of Glaukos by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier’s stock valued at $3,216,000 after acquiring an additional 128 shares in the last quarter. Values First Advisors Inc. purchased a new position in Glaukos in the 3rd quarter worth approximately $25,000. Inspire Investing LLC boosted its stake in Glaukos by 6.9% in the 3rd quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock worth $416,000 after purchasing an additional 206 shares during the period. AQR Capital Management LLC grew its holdings in Glaukos by 5.4% during the 2nd quarter. AQR Capital Management LLC now owns 4,141 shares of the medical instruments supplier’s stock valued at $490,000 after buying an additional 211 shares in the last quarter. Finally, Xponance Inc. raised its position in shares of Glaukos by 8.4% during the second quarter. Xponance Inc. now owns 3,118 shares of the medical instruments supplier’s stock valued at $369,000 after buying an additional 241 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

GKOS has been the subject of a number of research reports. Morgan Stanley upped their target price on shares of Glaukos from $100.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Citigroup lowered Glaukos from a “buy” rating to a “neutral” rating and raised their price objective for the company from $130.00 to $132.00 in a research report on Wednesday, July 10th. Truist Financial boosted their target price on Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Piper Sandler set a $140.00 price target on Glaukos in a report on Thursday, October 17th. Finally, Needham & Company LLC upped their price objective on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $130.45.

Insider Buying and Selling at Glaukos

In other news, Director Aimee S. Weisner sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now owns 30,119 shares of the company’s stock, valued at approximately $3,614,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Aimee S. Weisner sold 25,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $120.00, for a total value of $3,000,000.00. Following the transaction, the director now directly owns 30,119 shares in the company, valued at approximately $3,614,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,250 shares of company stock worth $4,825,873 over the last 90 days. Company insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

NYSE:GKOS opened at $130.59 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48. Glaukos Co. has a fifty-two week low of $59.22 and a fifty-two week high of $136.60. The firm has a market capitalization of $6.58 billion, a PE ratio of -45.34 and a beta of 1.02. The stock’s fifty day moving average is $129.07 and its 200 day moving average is $118.41.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). The business had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.55) earnings per share. On average, sell-side analysts anticipate that Glaukos Co. will post -2.16 earnings per share for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.